Interventional cardiology

Australian study gives tranexamic acid the safety tick in cardiac surgery

Concerns that the antifibrinolytic agent tranexamic acid may raise the risk of MI and stroke in patients undergoing cardiac surgery have been quashed after findings from a 10-year long trial finds no evidence to support these fears. Researchers from The Alfred in Melbourne who conducted the trial involving more than 4000 patients say theirs is ...

Already a member?

Login to keep reading.

© 2021 the limbic